IBM Stock Slides on CHIPS Award Finalization, Q2 Earnings Hangover

IBM's stock price has been declining due to the formalization of a $1 billion award under the CHIPS and Science Act by Anderon LLC, an IBM subsidiary. The company will use this funding to accelerate quantum wafer manufacturing research and development at its 300-millimeter foundry in Albany, New York.

The announcement was widely anticipated since May 2026, when a letter of intent was first disclosed, which had already driven IBM shares sharply higher at the time. However, instead of lifting the stock further, the official announcement appears to have prompted profit-taking by investors who had already positioned themselves around the expected outcome.

The decline in IBM's stock price is also attributed to the company's Q2 2026 earnings stumble, where it missed both top and bottom line estimates. This led management to trim its full-year revenue growth outlook, and multiple securities law firms launched investigations into the company. These unresolved issues have made investors hesitant to bid the stock higher.

The broader market backdrop is mixed, with the S&P 500 and Nasdaq modestly positive while the Dow Jones is slightly in the red. However, IBM's decline is notably steeper than the Dow's marginal dip, indicating that the selling pressure is company-specific rather than sector-wide.